Abstract
Rapidly progressive glomerulonephritis (RPGN) must be diagnosed and treated quickly to prevent irreversible organ injury. The commonest cause of RPGN is anti-neutrophil cytoplasm antibody (ANCA) associated small vessel vasculitis, and the most severe is anti-glomerular basement membrane (GBM) antibody disease. In this review we address pathogenesis, diagnosis, treatment and outcome in these two entities, with emphasis on novel therapies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Glomerular Basement Membrane Disease / therapy
-
Antibodies, Antineutrophil Cytoplasmic / analysis
-
Autoimmune Diseases / diagnosis
-
Autoimmune Diseases / immunology
-
Autoimmune Diseases / therapy
-
Diagnosis, Differential
-
Disease Progression
-
Glomerulonephritis / diagnosis
-
Glomerulonephritis / immunology
-
Glomerulonephritis / therapy*
-
Glucocorticoids / therapeutic use
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Methylprednisolone / therapeutic use
-
Plasma Exchange
Substances
-
Antibodies, Antineutrophil Cytoplasmic
-
Glucocorticoids
-
Immunosuppressive Agents
-
Methylprednisolone